Related Experiment Video

Updated: Jun 26, 2026

Methods for the Modulation and Analysis of NF-κB-dependent Adult Neurogenesis
14:58

Methods for the Modulation and Analysis of NF-κB-dependent Adult Neurogenesis

Published on: February 13, 2014

[NF-kappa B activation in peripheral blood mononuclear cells of children with epilepsy]

Jian-Ping Wang1, Ya-Qin Cao, Yi-Fan Su

  • 1Department of Pediatrics, People's Hospital of Gansu Province, Lanzhou 730000, China. wjpshengyiok@126.com

Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics
|January 20, 2009
PubMed

Insights

Nuclear factor-kappa B (NF-kappa B) activation in peripheral blood mononuclear cells (PBMC) is elevated in children with epilepsy. This activation correlates with seizure severity and decreases after treatment.

Area of Science:

  • Immunology
  • Neurology
  • Molecular Biology

Context:

  • Epilepsy is a chronic neurological disorder affecting millions of children worldwide.
  • Peripheral blood mononuclear cells (PBMC) play a role in immune responses.
  • Nuclear factor-kappa B (NF-kappa B) is a key transcription factor involved in inflammation and immunity.

Purpose:

  • To investigate the activation levels of NF-kappa B in the PBMCs of children diagnosed with epilepsy.
  • To determine the correlation between NF-kappa B activation and seizure severity in pediatric epilepsy.
  • To assess the impact of anti-epileptic treatment on NF-kappa B activation in these children.

Summary:

  • NF-kappa B activation was significantly higher in children with epilepsy compared to healthy controls.
  • Elevated NF-kappa B activation was observed across all epilepsy subgroups (systemic, partial, and unknown seizure types).
  • The systemic seizure group exhibited higher NF-kappa B activation than partial and unknown seizure groups, indicating a correlation with seizure severity. Treatment led to a significant reduction in NF-kappa B activation across all epilepsy subgroups.

Impact:

  • This study highlights NF-kappa B as a potential biomarker for epilepsy severity in children.
  • Findings suggest that targeting NF-kappa B pathways could be a therapeutic strategy for pediatric epilepsy.
  • Understanding the role of immune activation in epilepsy may lead to novel treatment approaches.
Abstract

More Related Videos

NF-κB-dependent Luciferase Activation and Quantification of Gene Expression in Salmonella Infected Tissue Culture Cells10:57

NF-κB-dependent Luciferase Activation and Quantification of Gene Expression in Salmonella Infected Tissue Culture Cells

Published on: January 12, 2020

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α11:27

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

Published on: November 2, 2018

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-kB-dependent Signaling Pathway02:26

NF-kB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...